^
Association details:
| Biomarker: | PTEN deletion |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer
Excerpt:
Forty-eight patients received trastuzumab (n = 39) or lapatinib (n = 9) combination chemotherapy...Among the patients with responsive disease, time to best response did not differ by PTEN status, but the duration of response was significantly shorter for patients with PTEN loss (median 4.2 vs. 6.1 months, p = 0.04). In addition, patients with PTEN loss had a significantly shorter progression-free survival time (median 4.9 vs. 7.3 months, p = 0.047).
Secondary therapy:
Chemotherapy
DOI:
10.1159/000366426
